Why the study?
Coronary heart disease pathophysiology involves inflammation, and antibiotics hold anti-inflammatory and anti-oxidative properties that may theorize reductions in cardiovascular events. This article critically appraises a systematic review assessing antibiotics for secondary prevention.
Do antibiotics prevent cardiovascular events in patients with coronary heart disease?
Do antibiotics prevent cardiovascular events in patients with coronary heart disease?
This article critically appraises a systematic review on the use of antibiotics for the secondary prevention of coronary heart disease.
Antibiotics should not inform secondary CHD prevention; this appraisal leaves open the need for updated rigorous trials.
It is estimated that 200 million people are living with coronary heart disease, which remains one of the leading causes of mortality and morbidity worldwide. Those living with coronary heart disease are at an increased risk of cardiovascular events such as stroke, myocardial infarction, and cardiovascular death. Pathophysiology of coronary heart disease revolves around inflammation which leads to plaque build-up. Antibiotics are known to hold anti-inflammatory and anti-oxidative properties. It is theorized that reductions in inflammation could prevent cardiovascular events which may reduce suffering, risk of death and hospital admission rates in patients with coronary heart disease. This article critically appraises a systematic review that assessed the risk of antibiotics used as secondary prevention for coronary heart disease.
No takes yet. Share an insight, caveat, or question.
Mansoor et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: